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Abstract
Intro - Differences in anesthetic technique when using propofol, remifentanil and fentanyl can
result in different emergence and nociception outcomes. After surgery, a brief emergence period
combined with an extended duration of analgesia is desired. We propose to use pharmacokinetic
(PK)1−4 and pharmacodynamic (PD)5,6 models to find optimized ratios of propofol and remifen-
tanil to shorten emergence time and extend the time until inadequate analgesia is experienced dur-
ing patient recovery. Modeling has been used to find the optimum effect site concentrations (Ces)
for rapid wake up7; however, an optimization technique which also accounts for analgesic effect is
desirable. Method - Anesthesiologists gave general anesthesia to 21 patients for laproscopic pro-
cedures using propofol, remifentanil, and fentanyl using a standard of care anesthetic technique.
Baseline model predictions for Ces were calculated for remifentanil, fentanyl, and propofol. PD
response surface models were used to calculate the probabilities of unconsciousness and response
to noxious stimulus (30 PSI tibial pressure algometry, a surrogate of postoperative pain) during
and after the anesthetic. Post-hoc optimized PK and PD model predictions were made for both
sedation and analgesia by varying the ratio of propofol and remifentanil Ces, constrained to the
same or higher PD model predicted probabilities, and leaving fentanyl Ces unchanged from base-
line. For each patient, optimized changes to the recorded propofol and remifentanil infusions were
made every 5 minutes during the general anesthetic. The theoretical improvement provided by
the optimization was measured by comparing the time differences between the baseline model
predictions and the optimized prediction of the emergence time and time to inadequate analgesia.
Results - The baseline model predictions found an average emergence time of 8.2 ± 5.6 minutes
after end of surgery and a duration of analgesia of 9.9± 13.6 minutes after patient emergence. The
optimized remifentanil and propofol Ces theoretically reduced the emergence time to 3.9± 1.6 (p
< 0.01, t-test) minutes and increased the duration of adequate analgesia to 15.4 ± 12.5 (p < 0.05,
t-test) minutes. Discussion - Optimized ratios of propofol and remifentanil resulted in a theo-
retically shorter emergence time and a longer period of adequate postoperative analgesia. These
results require clinical verification in a new study, but the optimization algorithm shows potential
for real-time clinical guidance in drug management.
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Introduction
Population models predict the pharmacodynamic and pharmacokinetic effects and interactions
between propofol and remifentanil. 1−6 Pharmacokinetic approximations of drug bio-distribution
are used to translate anesthetic drug administrations to pharmacodynamic estimations of expected
responses to noxious stimuli. Assuming these approximations and estimations correctly depict the
patient’s state of anesthesia, we hypothesize to decrease the expected emergence time (return of
consciouness, ROC) and extend the period of adequate analgesia (return of nociception, RON).
Vuyk et al. found concentration ratios for Propofol with either Remifentanil, Fentanyl, Alfen-
tanyl, or Sufentanil to decrease ROC. 7 Virtual simulations were performed on virtual patients
using pharmacodynamic and pharmacokinetic models. Four different infusion durations were
run at two different pharmacodynamic levels. The optimal concentrations were dependent on the
infusion length and pharmacodynamic level.7
The algorithm is to be tested with post-hoc simulations but will be validated and used clinically
in future studies and therefore needs to be robust for varying surgery lengths and levels.
Methods
Anesthetically relevant data was recorded from 21 surgeries. Pharmacokinetic and pharmacody-
namic models were applied to each of the anesthestic administrations. An optimization algorithm
was theoretically run post-hoc with the same pharmacodynamic levels but with different remifen-
tanil effect site concentrations (Res) and propofol effect site concentrations (Pes). The ROC and
RON times will be the comparison metric for the simulated times from in vivo administrations
and the simulated times from the administrations of the optimization algorithm.
Surgical Procedure
Anesthesiologists gave general anesthesia to 21 patients for laproscopic procedures adminis-
tering propofol, remifentanil, and fentanyl via TIVA and a standard of care anesthetic technique.
Midazolam and rocuronium were also administered to each of the patients. A study investigator
was present for each of the cases to record; the surgical events, the anesthetic events, the adminis-
tered drug doses, the return of consciousness time, OAA/S (observers assessment of alertness and
sedation) scores , and patients’ physical characteristics (age, sex, height, and weight). The average
surgical time was 165± 96 minutes. This database of patient drug administrations and vitals was
collected by Johnson et al. in a previous study that evaluated pharmacodynamic response surface
models. 6 More patient information is included in the appendix.
Pharmacokinetic and Pharmacodynamic Simulation
The three compartment pharmacokinetic model8, was used to calculate effect site concentra-
tions (Ce) using volumes and clearances from Schnider, Minto, and Schafer. 1−4,9 Fentanyl C ′es
were converted to a remifentanil equivalent using the equivalence ratio of 1:1.2. 6 All data analy-
sis and simulations were calculated in Matlab. The Greco parmacodynamic model predicted the
expected responses to various stimuli, as shown in equation 1, the parameters are listed in table 2.
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Stimulus C50P C50R α y
OAA/S < 2 2.2 33.1 3.65 4.99
Laryngoscopy 5.6 48.9 33.2 2.2
Algometry 4.16 8.84 8.2 8.34
Table 1: Response surface parameters
Where E is the probability to effect, Emax is the maximal possible effect. Cp and Cr are the
effect site propofol and remifentanil concentrations. C50p and C50r are the individual effect site
concentrations that produce 50% of the maximal effect. α and γ are the curve fitting fitting param-
eters.
Optimization Algorithm
The algorithm uses the pharmacodynamic effect for the administered remifentanil, propofol,
and fentanyl infusions. Every five minutes after induction the algorithm finds a new optimal
concentrations for remifenatnil and propofol, the fentanyl concentrations are kept the same.
The optimalCp andCr pair is dependent upon the past infusions10 and the remaining duration
of surgery7. To find alternative Cp and Cr pairs, the equipotent pharmacodynamic levels are
found for both laryngoscopy and OAA/S > 2 from the administered Ces. There are two options:
either increase the Cr and decrease the Cp while following the OAA/S < 2 isobole or increase
the Cp and decrease the Cr along the laryngoscopy isobole. Infusions are changed according to
the pharmacokinetic models to maintain each Ces with the correst pharmacokinetic compartment
amounts for an estimated approximation of the remainder of surgery.
The ROC and RON times are calculated for each Cp and Cr pair by tracking the drug elimina-
tion over the pharmacodynamic response surface model.
ROC (min) = (time at 50 % OAA/S < 2)-(time at end of surgery)
The end of surgery is the point when one of the infusions are terminated. ROC is the elapsed
time until the Ce’s cross the 50 % isobole on the pharmacodynamic OAA/S < 2 surface.
RON is the time when decreasing Ces are between the 50% OAA/S < 2 isobole and the 25 %
algometry isobole.
RON (min) = (time at 25 % algometry isobole)- (time at 50 % OAA/S < 2)
The ROC and RON times each have a parabolic shape. For easier computation the parabolas
are interpolated using numerical linear least squares. Cubic splines were tested but required more
calculated points for accuracy than the least squares method.
Our goal is to find the minimum ROC time and the maximum RON time. The optimal Ce
is also dependent upon the anesthesiologist’s priority on ROC versus RON. Let WROC be the
percentage of weight on ROC and WRON for RON. Minimizing the function (eq. 2) of the linear
combination of the weights, ROC times, and RON times allows for an easy investigation for the
optimal concentration. The function f will be a continuous piecewise function with a parabolic
shape.
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Figure 1: Original effect site concentrations as administered by the anesthesiologist during surgery.
For this example the data collection started about 17 minutes before the intial dose was adminis-
tered. The drug wash out was plotted for 100 minutes after the end of surgery.
f = WROC ∗ (ROC)−WRON ∗ (RON) (2)
Post-hoc simulation provides the exact remaining surgery time. To avoid the technique from
knowing exatly when the surgery would end an estimated surgery end was used until the last
ten minutes of surgery. The estimated end of surgery is the end of surgery rounded down to the
nearest half hour. We assumed the anesthesiologist would have an idea of when the surgery will
end to the nearest thirty minutes. For the last optimization with less than ten minutes left in the
surgery a Re limit of 10 ngml was enforced to avoid respiratory compromise.
Assessment of optimization performance
Vuyk’s assesment was stricly ROC time for the simulated results. We want to compare the
ROC and RON times between the simulated in vivo administrations with the simulated optimized
administrations.
We will run the optimization on all 21 surgeries five different times, each with a different
weight ratio. The average ROC and RON times for the 21 surgeries will be recorded for each
weight. Also the average difference between each simulated ROC and RON times and the con-
trol ROC and RON times will be reported, as the average possible improvement. A student t-test
(the function ttest in matlab) will be calculated five times, for each weight, between the control
times and the simulated times. We’re assuming a p-value for the student t-test of p < .05 implies
statistical independence.
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Figure 2: Original dosing vs optimized dosing, using weights roc = .9 and ron = .1.
Results
Post-hoc simulations were performed on 21 laproscopic surgeries, to find optimal pharmacody-
namic equipotent administrations. The optimized Cp and Cr for surgery # 15 withWROC = .9 and
WRON = .1, when 90 % priority was given to ROC and 10 % to RON, are shown in fig. 2. These
alternative Ce decrease the expected ROC time from 7.6 to 5.2 minutes while increasing the RON
time from 6.3 to 9.3 minutes as seen in fig. 3.
The optimization was performed for each of the 21 surgeries with 5 different weights. The
average ROC and RON times with standard deviations for each of the 5 weights versus the control
are shown in table 2 and fig. 4. Delta is listed to show the average theoretical improvement for
each surgical case from 2 - 5 minutes shorter ROC time and 3 - 19 minutes extended RON time.
WROC values less than .6 are not shown because the results found are very similar, in almost all
of the simulations every optimized dosing for WROC < .6 was exactly the same as the optimized
dosing for WROC = .6.
Discussion
The results show that Pk and Pd models can be used to find equipotent effect site concentrations
(Ce) of Propofol and Remifentanil that either shorten ROC time or lengthen RON time. However
when 85 % of the priority was given to ROC and 15 % to RON (WROC = .85, WRON = .15)
then both the ROC time was decreased and the RON time was increased by an average of 2.51
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Figure 3: Close up of the end of surgery # 15 with the ROC and RON times for both the con-
trol(origina) and optimized simulations.
Wroc Wron mean ± std (min) P-value ∆ (min) 95% CI
ROC Times
Control 8.20± 5.63
1 0 3.70± 1.63 < .001 5.15 5.08→ 5.22
.95 .05 4.14± 1.99 < .001 4.72 3.82→ 5.62
.9 .1 5.20± 3.17 .002 3.65 2.23→ 5.07
.85 .15 6.34± 3.03 .04 2.51 1.15→ 3.87
.6 .4 6.95± 2.95 .12 1.899 .58→ 3.22
RON Times
Control 9.91± 13.57
1 0 11.95± 13.21 .23 3.02 −1.32→ 8.92
.95 .05 11.33± 10.57 .247 2.40 0→ 7.12
.9 .1 12.30± 11.08 .13 3.37 0→ 8.33
.85 .15 15.89± 12.29 < .01 6.95 1.45→ 12.45
.6 .4 18.98± 13.34 < .001 18.98 13.02→ 24.94
Table 2: Comparing the wake up and nociception times with the original administration. The
values are found using the 21 surgeries for each coefficent. The p-value, is acquired using the
t-test of the optimized wake up times and nociception times against the control times. ∆ is the
average difference for each simulated surgery with the control surgery. The 95% CI is the 95
percent confidence interval around ∆ using the standard error.
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Figure 4: The normal administration (red) in comparison to the optimized administrations for
five different weights. The bars indicate the standard deviation, the averages are where the two
bars meet. Note the curve made by the averages of the optimizations shows the tradeoff dilema
between wake up time and time until pain.
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minutes and 6.95 minutes respectively. These results are an average of 21 different surgeries and
are theoretical thus require clinical validation.
Optimal concentrations that minimize ROC time and maximizes RON time depend upon the
priorities indicated by the anesthesiologist. The anesthesiologist’ priority for minimizing ROC
versus RON is like a dial. The assigned weights are the percentage of priority to the outcome of
either ROC or RON. The weights will be chosen before each surgery dependent upon the patient
and the surgery for a more personalized medicine.
To optimize Cp and Cr, anesthetic levels of hypnosis and sedation can not be compromised.
The hypnotic and sedation levels are assumed to be represented by the pharmacodynamic re-
sponse surface model of Laryngoscopy and OAA/S < 2, respectively. The OAA/S < 2 model is
the Observers Assesment of Alertness and Sedation response to shake and shout. The surrogate
for adequate analgesia or post-operative pain (nociception) is the pharmacodynamic response sur-
face model of 30 psi tibial pressure algometry.
The technique is constrained to use the Propofol and Remifentanil administrations during
the induction period and all of the Fentanyl administrations. To avoid respiratory depression
Remifentanil Ces must be below 10 ngml by the end of surgery.12,13
How useful is this recommended dose for the anesthesiologist since it is using population phar-
macodynamic models? The technique finds the concentration ratios with the optimal elimination
profiles from the body. It may not be the exact time for that patient, but it should be the best exit
track from the surgery for that patient. There is variability that causes general assumptions: high
drug tolerance changes the actual C50 values and the ROC/RON slopes and variability in cardiac
output and blood flow alter the rate constant ke0.
How reliable is this recommendation since Vuyk’s fastest emergence time is 5.1 minutes while
ours is 3.7 minutes? The shorter emergence time may be cause by multiple factors; different phar-
macodynamic and pharmacokinetic model parameters, Vuyk’s infusions were steady (causing
drug accumulation in, the slow compartment, V3), the different classification in return of con-
sciousness, and the different remifentanil to fentanyl potentcy ratio.
Vuyk’s optimization pioneered the concept to target alternative Ces for minimal ROC time.
This is not used clinically because anesthesiologist know adequate analgesia is also requisite. An-
other reason is because only four surgery lengths were tested with two pharmacodynamic levels.
All three of these issues were overcome with the proposed technique. We expect this concept to be
generalized to more drugs and be used in the operating room
This technique showed expected improvement for ”typical” cases and we expect has the capa-
bility to vastly optimize longer or complex surgeries, when the slow equilibrating tissue compart-
ment saturates. This technique analyzed remifentanil and propofol which are fast acting drugs;
the possibility for more drastic results are expected if slower acting drugs were used. This is what
Vuyk et al. found as well that with just using remifentanil over fentanyl, alfentanil, or sufen-
tanil decerased the average wake up times by a factor of 1.5-3. This optimization technique will
be able to help the anesthesiologist achieve a better understanding of the anesthetic orientation
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Appendix
Put the patient information here. Anything that seems viable like all the ages, heights, ...
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